Trimetazidine
- Generic Name
- Trimetazidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O3
- CAS Number
- 5011-34-7
- Unique Ingredient Identifier
- N9A0A0R9S8
- Background
Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.
...
- Indication
Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
- Associated Conditions
- Angina Pectoris, Chronic Stable Angina Pectoris, Tinnitus, Vertigo, Decreased visual acuity caused by Vascular Disorders
- Associated Therapies
- -
Trimetazidine Therapy in Hypertrophic Cardiomyopathy
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- University College, London
- Target Recruit Count
- 90
- Registration Number
- NCT01696370
- Locations
- 🇬🇧
The Heart Hospital, UCLH, London, United Kingdom
Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2006-01-26
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 30
- Registration Number
- NCT00282360
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath